References
1. Aithal G. P., Day C. P., Kesteven P. J. L., Daly A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications // Lancet. - 1999. - Vol. 353. - P. 717-719.
2. Aynacioglu A. S. et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin // Brit. J. Clin. Pharmacol. - 1999. - Vol. 48. - P. 409-415.
3. Breckenridge A., Orme M., Wesseling H. et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man // Clin. Pharmacol. Ther. - 1974. - Vol. 15. - P. 424-430.
4. Bodin L., Verstuyft C., Tregouet D.-A. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity // Blood. - 2005. - Vol. 106, № 1.
5. Cropp J. S., Bussey H. I. A review of enzyme induction of warfarin metabolism with recommendations for patient management // Pharmacotherapy. - 1997. - Vol. 17. - P. 917-928.
6. Gaikovitch E. A., Cascorbi I., Przemyslaw M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population // Eur. J. Clin. Pharmacol. - 2003. - Vol. 59. - P. 303-312.
7. Guo Y., Zhang Y., Wang Y. et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans // DMD. - 2005. - Vol. 33. - P. 749-753.
8. Leung A. Y. H., Chow H. C. H., Kwong Y. L. et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients (Brief report) // Blood. - 2001. - Vol. 98, № 8.
9. Meisel C., Roots I., Cascorbi I. et al. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport // Clin. Chem. Lab. Med. - 2000. - Vol. 38. - P. 869-876.
10. OReilly R. A. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy // Arch. Intern. Med. - 1981. - Vol. 141. - P. 458-459.
11. OReilly R. A. Studies on the optical enantiomorphs of warfarin in man // Clin. Pharmacol. Ther. - 1974. - Vol. 16. - P. 348-354.
12. OReilly R. A. The stereoselective interaction of warfarin and metronidazole in man // N. Engl. J. Med. - 1976. - Vol. 295. - P. 354-357.
13. OReilly R. A., Aggeler P. M. Determinants of the response to oral anticoagulant drug in man // Pharmacol. Rev. - 1970. - Vol. 22. - P. 35-96.
14. OReilly R., Rytand D. Resistance to warfarin due to unrecognized vitamin K supplementation // N. Engl. J. Med. - 1980. - Vol. 303. - P. 160-161.
15. OReilly R. A., Trager W. F., Rettie A. E. et al. Interaction of amiodorone with racemic warfarin and its separated enantiomorphs in humans // Clin. Pharmacol. Ther. - 1987. - Vol. 42. - P. 290-294.
16. Takahashi H., Ieiri I., Wilkinson G. R. et al. 5- Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients (Brief report) // Blood. - 2004. - Vol. 103, № 8.
17. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment // Ibid. - 2000. - Vol. 96, № 5.
